CUV recruits 200 patients in Phase III vitiligo trial CUV105
Filed with ASX · · 4 pages · English
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL renews share buy-back program
- Positive preliminary results for PRENUMBRA Instant in stroke
- Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025
- Half Year Results Announcement
- Preliminary results from SCENESSE adolescent EPP study
Later from Clinuvel Pharmaceuticals
- CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
- CLINUVEL management update
- Study confirms NB-UVB needed to activate repigmentation
- CLINUVEL preparing upgrade of ADR program, NASDAQ uplist
- CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals